Search 

Curon Biopharmaceutical, founded in June 2018, is a biopharma company with facility in Shanghai focusing on developing next generation anti-cancer therapies. It completed a $150 million USD Series A financing led by 6 Dimensions Capital, Boyu Capital, and Temasek. With its internationally experienced senior executive management team, Curon Biopharma currently holds multiple promising novel cancer immuno-therapeutic agents in its pipeline and is committed to bring next generation cancer immunotherapies to patients. Curon strives to accelerate its pipeline assets clinical development, further expand its portfolio through in-licensing and other forms of collaboration with biotech and pharmaceutical companies around the world to bring more effective treatment options to patients.

Real-time Data Aggregation and analytics in real-time

We support companies gather information and analyze information in real-time speed access to insight facts and evidence into suppliers, vendors. partners and customers

Guoqian Venture Capital is one of the two business platforms; the other is Guoqian Medical Technology Innovation Research Institute, which is an incubator/accelerator for startup and growth companies.
Guoqian Venture Capital is a professional and market-oriented venture capital firm that focuses on equity investment in early innovation and entrepreneurship projects in the fields of medical devices, in vitro diagnostic reagents and biotechnology. Focusing on innovative technologies and products. Due to currency restrictions, the firm can only invest in entities in China. The investment size is from ￥5 million （$750k) to ￥20 million ($ 3 million).
Guoqian Medical Technology Innovation Research Institute is committed to cultivating cutting-edge technologies and projects in Chinese medical device industry, and providing it with multi-faceted technologies, policies, talents, industrialization and markets through direct investment, entrepreneurial services, and scientific and technological achievement transformation services. Integration of services and resources to create an innovative platform for national technological innovation and industrial integration and empowerment. At the same time, it has also become an enabling platform for post-investment enterprises of Guoqian Fund. By creating industrial clusters and industrial ecology, it will provide post-investment management, post-investment services, and post-investment empowerment to post-investment enterprises.
Based on the business philosophy of “achieving the dreams of others”, Guoqian Medical uses market-oriented and specialized equity investment funds to create industrial agglomeration and industrial ecology; it empowers post-investment enterprises by creating industrial agglomeration and industrial ecology. The two platforms complement each other, and strive to build a medical device industry cluster and ecosystem in Suzhou High-tech Zone in 10 years, becoming one of the main promoters of the domestic medical device industry.

HebeCell was founded in 2016 by industry leading inventors in developing the manufacturing platform of hematopoietic cells from human pluripotent stem cells (PSCs). Their first-in-class proprietary 3D manufacturing platform for human iPS-NK cells is feeder-free, designed specifically for single-use-bioreactor at industrial scale. HebeCell’s platform will accelerate the application of PSCs as a viable source of immune cells in the next generation of immune cell therapies for immune-Oncology, autoimmune and infectious diseases.

Dr. John Lu is the President and CEO of HebeCell. Before establishing HebeCell, John was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which in 2016 was acquired by Astellas, the second-largest pharmaceutical company in Japan. John is an expert in stem cell biology and regenerative medicine with 20 years of experience in the field.

Dr. Allen Feng is the Chief Scientific Officer of the HebeCell Corp. Prior to establishing HebeCell, he was the Director of Cell Biology of Semma Therapeutics, which was acquired by Vertex Pharmaceuticals in 2019. Prior to Semma, Allen worked as R&D Head of Stem Cell Bioprocessing Group at EMD Millipore, and also served as Director and Senior Scientist at Advanced Cell Technology /Ocata Therapeutics.

INOVOTION is a biotech company which offers you a unique in vivo technology dedicated to oncology and immuno-oncology efficacy studies and early toxicity evaluations.
Our Fast, Sensitive, Reliable and Affordable assay will save you time and money, to give you a clear competitive advantage.
This breaking-thought technology, based on chick embryo, provides early analysis of your anti-cancer treatments before the classical preclinical stages. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process, increases your R&D productivity and reduces its costs.
It’s rapid Go/No Go decision with multi-cancer screening capacities.
This next generation of in vivo efficacy and toxicity tests covers fours main aspects:
- EFFICACY assays for your treatments in oncology and immuno-oncology
- EARLY TOXICITY assays for your drug candidates
- TARGET VALIDATION in oncology
- MULTI-CANCER SCREENING to (re)positioning your treatment

NLC European Healthcare Venture Builder 是一家总部位于荷兰的欧洲医疗科技企业创设公司,在法国、德国和奥地利设有分支机构。NLC 每年筛选超过 3,000 项欧洲最新的医疗专利技术和发明,从中挑选出最具潜力的创新技术并创建公司。NLC 旗下已拥有数十家医疗科技企业,横跨治疗设备、诊断、影像、细胞疗法、AI 人工智能、神经网络、智慧医疗等国内热门医疗领域和紧缺方向,且在技术成熟度、治疗领域和技术类型上拥有充分的多样性,进一步分散了投资风险。

We are a corporate finance firm committed to advancing the field of Healthcare through advisory,and investments.

We advise and buy-side and sell side corporates and Family offices on investment in Healthcare & life Sciences across Switzerland, Europe and the US.

The founder team of PreOmics started working on optimized LC-MS proteomic workflows at the Matthias Mann lab in 2010. After establishing an optimized and easier sample preparation process in 2014, Dr. Nils A. Kulak together with Dr. Garwin Pichler set forth to validate their technologies with external laboratories and researchers. With a lot of support of proteomics experts, engineers and industry designers, they made their first product ready-for-market. The PreOmics team won several awards for their business idea, were supported by various accelerator programs and established their company in the beginning of 2016. They are now located at the IZB in Martinsried just south of Munich.
We empower our clients in life science to establish biological knowledge through efficient reliable solutions and workflows that set the standard for protein analysis. Our team spirit, energy and commitment empower us to be creative and quality focused. A trusted partner with deeply rooted scientific experience.

Strategikon Pharma is the developer of Clinical Maestro™, which is an end-to-end elegant cloud-based platform to more efficiently budget, source and manage complex clinical programs. We believe that intuitive technology, complete transparency and effective communication between biopharmaceutical companies and providers will revolutionize the productivity of clinical research.

Clinical Maestro™: Modernize the outsourcing